Dr. John Cush RheumNow
4 years 7 months ago
Dr Virginia Steen at #RWCS2022. On scleroderma lung Dz that worsens outcomes https://t.co/n7IV8UVI2N https://t.co/kLmiKiseur
Dr. John Cush RheumNow
4 years 7 months ago
Rheumatoid Arthritis Nonadherence is Multifactorial
A 6-month prospective cohort study of RA patients shows NA to vary according to drug type and be related to psychological, communicational, logistic, sociodemographic or clinical factors.
https://t.co/FWamPS2fTQ https://t.co/EtoStfdTsI
Dr. John Cush RheumNow
4 years 7 months ago
Dr Eric Ruderman presents on paraneoplastic syndromes. Many autoantibodies have been possibly implicated. #RWCS2022 https://t.co/n7IV8UVI2N https://t.co/xx54hAKY3C
Dr. John Cush RheumNow
4 years 7 months ago
1st approved Rx for neuromyelitis optical (Device syndr). Eculizumab, C5a inhibitor, weird effective at preventing relapses of NMO #RWCS2022 https://t.co/n7IV8UVI2N https://t.co/a6LyTi3LXL
Dr. John Cush RheumNow
4 years 7 months ago
Dr Eric Ruderman presents treatment of Stiff Man syndrome why muscle relaxants, benzos, IVIG?? Poor outcomes nevertheless #RWCS2022 https://t.co/n7IV8UVI2N https://t.co/xDXJCM34aO
Dr. John Cush RheumNow
4 years 7 months ago
Dr Eric Ruderman presents on rare Stiff Man syndrome at #RWCS2022 https://t.co/n7IV8UVI2N
Dr. John Cush RheumNow
4 years 7 months ago
EMA has posted its intent to review the safety of JAK inhibitors used to treat several chronic inflammatory disorders (RA, PsA, JIA, AS, UC, atopic dermatitis) based on the release of the Pfizer tofacitinib A3921133 study https://t.co/loG7zWBWHs
Dr. John Cush RheumNow
4 years 7 months ago
Mortality of Cryoglogulinemia has declined between 1999 and 2018 freom 0.4 deaths per million to 0.19. Cryo found in 39% of HCV(2009–2013) down to 26% (2014–2018). Prevalence and deaths dropped witn introduction of HCV antiviral Rx https://t.co/h9rL1ftI0n
The European League against Rheumatism (EULAR) has developed recommendations for cardiovascular risk (CVR) management in rheumatic disease patients based on literature review and expert consensus.
Dr. John Cush RheumNow
4 years 7 months ago
Challenges in Lupus:
-Mortality greatest in 1st yr
-Dx Delays 6.4 yrs
-Long-term complications increased 50 fold
-Steroids worsen long-term outcomes
-Health care costs increased 3 to 5 years prior to Dx
-Mean delay in drug starts after Dx =177 days https://t.co/QUbsIQtcRa https://t.co/zAMUp99ecg
The consequences of medication non-adherence (NA) in rheumatoid arthritis (RA) care are numerous and damaging. A 6-month prospective cohort study of RA patients shows NA to vary according to drug type and be related to psychological, communicational, logistic, sociodemographic or clinical factors.
Dr. John Cush RheumNow
4 years 7 months ago
Olumiant (baricitinib) studies in Lupus halted by Lilly due to mixed results in phase 3 trials. While the BRAVE-1 study showed 4-mg BARI meeting primary endpoint at 52 weeks; the Brave-II failed to do same & failed key secondary endpoints https://t.co/XBmo15UCYl
Dr. John Cush RheumNow
4 years 7 months ago
Lupus international cohort study of 1460 HCQ pts showed that SLE flares were increased with dose reduction (aHRs 1.20;CI 1.04 to 1.38) and HCQ discontinuation (aHR 1.56; 1.31 to 1.86), higher with low educational levels after HCQ D/C https://t.co/fO4fBtrFYo
Dr. John Cush RheumNow
4 years 7 months ago
Fatigue in Early RA registry - study of n = 1236 pts w/ Dz duration 11 mos. The prevalence rates of fatigue was 44% and severe fatigue 19% and was stable over 3 yrs. Greater fatigue in women, high pain, mental Dz, function; BUT NOT SJC or ESR https://t.co/hEgPbsAqYZ
Dr. John Cush RheumNow
4 years 7 months ago
Taiwan study of 12,786 pre-dialysis advanced CKD patients with gout shows that use of febuxostat or allopurinol was assoc w/ a reduced sepsis/infection risk - most w/ FEB (HR, 0.68; 0.52–0.87), but no signif difference in MACE or CVA https://t.co/zp7JLwzah8
